Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase NA 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 27Prostatic Hyperplasia 3Neoplasms 3Urinary Bladder Neoplasms 1Recurrence 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Lower Urinary Tract Symptoms 1Erectile Dysfunction 1Adenocarcinoma of the Prostate 1

Interventions

Dutasteride 3acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2proxalutamide 1polyphenon E 1mirabegron 1TroVax 1Transurethral Resection of Prostate 1Transurethral Resection of Bladder 1Therapeutics 1Tamsulosin 1Standard of Care 1Risedronic Acid 1Radiotherapy 1Psychiatric Rehabilitation 1Prostatectomy 1Papaverine 1Oxygen 1Nitrous Oxide 1Needles 1Microspheres 1Lycopene 1Levofloxacin 1Finasteride 1Electroacupuncture 1Doxazosin 1Docetaxel 1Diclofenac 1Dexmedetomidine 1Cystoscopy 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Prostatic Hyperplasia × Dutasteride × Clear all
NCT06001619 2023-08-21

PROMED

Turku University Hospital

Phase 4 Recruiting
100 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT00375765 2017-01-19

Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer

GlaxoSmithKline

Phase 4 Completed
40 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

NCT00706966 2014-01-17

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer

University of California, San Francisco

Phase NA Completed
10 enrolled 14 charts
Genitourinary

Neoplasms, Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡